Table 1.
Distribution of site, clinical staging, histopathological differentiation of OSCC, and their IHC reactivity.
| Distribution category | Total number | IHC reactivity | |||
|---|---|---|---|---|---|
| Positive (n) | Negative (n) | % of positive reactivity | P | ||
| Site |
0.282 NS |
||||
| Alveolus | 11 | 07 | 04 | 63.63 | |
| Buccal mucosa | 13 | 05 | 08 | 38.46 | |
| Tongue | 15 | 05 | 10 | 33.33 | |
| Lip | 01 | 01 | 00 | 100 | |
|
| |||||
| Clinical staging |
0.867 NS |
||||
| Stage I | 06 | 03 | 03 | 50 | |
| Stage II | 07 | 04 | 03 | 57.14 | |
| Stage III | 13 | 05 | 08 | 38.4 | |
| Stage IV | 14 | 06 | 08 | 42.8 | |
|
| |||||
| Histopathological differentiation | |||||
| WDSCC | 13 | 09 | 04 | 69.23 | 0.011 S |
| MDSCC | 16 | 08 | 08 | 50 | |
| PDSCC | 11 | 01 | 10 | 9.09 | |
|
| |||||
| OSCC (total) | 40 | 18 | 22 | 45 | |